Christopher Peetz Sells 7,098 Shares of Mirum Pharmaceuticals (NASDAQ:MIRM) Stock

Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) CEO Christopher Peetz sold 7,098 shares of the company’s stock in a transaction on Thursday, January 22nd. The stock was sold at an average price of $93.33, for a total value of $662,456.34. Following the sale, the chief executive officer owned 163,733 shares of the company’s stock, valued at $15,281,200.89. The trade was a 4.15% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.

Mirum Pharmaceuticals Price Performance

Mirum Pharmaceuticals stock opened at $94.29 on Friday. The company has a debt-to-equity ratio of 1.06, a quick ratio of 3.16 and a current ratio of 3.31. Mirum Pharmaceuticals, Inc. has a 52 week low of $36.88 and a 52 week high of $96.84. The stock has a market capitalization of $4.85 billion, a P/E ratio of -109.64 and a beta of 0.48. The stock has a fifty day moving average of $77.33 and a 200-day moving average of $70.78.

Mirum Pharmaceuticals (NASDAQ:MIRM) last released its quarterly earnings data on Tuesday, November 4th. The company reported $0.05 earnings per share for the quarter, beating the consensus estimate of ($0.10) by $0.15. The business had revenue of $133.01 million for the quarter, compared to analyst estimates of $130.11 million. Mirum Pharmaceuticals had a negative return on equity of 16.47% and a negative net margin of 8.78%.Mirum Pharmaceuticals’s revenue was up 47.1% compared to the same quarter last year. During the same period last year, the firm posted ($0.30) earnings per share. On average, sell-side analysts expect that Mirum Pharmaceuticals, Inc. will post -1.43 earnings per share for the current fiscal year.

Trending Headlines about Mirum Pharmaceuticals

Here are the key news stories impacting Mirum Pharmaceuticals this week:

• Positive Sentiment: Baird updated Mirum’s valuation after the company reported a beat-and-raise on results, a development that supports upside and follows recent analyst price-target increases. Baird updates Mirum valuation
• Positive Sentiment: Multiple brokerages have raised targets/ratings in recent weeks (Morgan Stanley, HC Wainwright, Stifel, Robert W. Baird and others), reflecting confidence in revenue growth and the company’s lead product (maralixibat). These upgrades help underpin higher consensus price targets. MarketBeat analyst notes
• Neutral Sentiment: Company fundamentals: Mirum is a late-stage biopharma focused on rare cholestatic liver diseases; recent quarter showed strong revenue growth and an EPS beat, but the company remains loss-making on GAAP metrics and carries leverage. This context supports analyst optimism but also ongoing execution risk. Company profile and results
• Neutral Sentiment: Institutional activity shows modest position changes by funds (small buys/sells), not a clear directional institutional shift. Institutional holdings
• Negative Sentiment: Significant insider selling: several senior executives sold shares on Jan. 22 — CEO Christopher Peetz (7,098 shares), COO Peter Radovich (2,382), CFO Eric Bjerkholt (1,421), SVP Jolanda Howe (926) and insider Joanne Quan (multiple recent sales). The block of insider sales (each at ~\$93.33) reduces insider ownership and is likely weighing on sentiment and the stock today. Insider trades alert

Wall Street Analysts Forecast Growth

MIRM has been the subject of several research reports. Citizens Jmp increased their price objective on shares of Mirum Pharmaceuticals from $95.00 to $140.00 and gave the company a “market outperform” rating in a research note on Friday, December 19th. Cantor Fitzgerald reiterated an “overweight” rating and issued a $130.00 price target on shares of Mirum Pharmaceuticals in a research note on Monday, December 8th. Morgan Stanley boosted their price objective on Mirum Pharmaceuticals from $81.00 to $95.00 and gave the stock an “overweight” rating in a research report on Tuesday, December 9th. Robert W. Baird upped their target price on Mirum Pharmaceuticals from $80.00 to $88.00 and gave the stock an “outperform” rating in a report on Monday, December 8th. Finally, Evercore ISI reiterated an “outperform” rating and issued a $101.00 target price on shares of Mirum Pharmaceuticals in a research report on Tuesday. One analyst has rated the stock with a Strong Buy rating, twelve have assigned a Buy rating and one has given a Sell rating to the company. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $102.58.

Institutional Trading of Mirum Pharmaceuticals

Institutional investors have recently modified their holdings of the business. MCF Advisors LLC raised its position in Mirum Pharmaceuticals by 76.4% during the 3rd quarter. MCF Advisors LLC now owns 427 shares of the company’s stock worth $31,000 after purchasing an additional 185 shares during the last quarter. Quantbot Technologies LP bought a new stake in shares of Mirum Pharmaceuticals in the 3rd quarter valued at about $33,000. Comerica Bank increased its stake in shares of Mirum Pharmaceuticals by 45.1% in the first quarter. Comerica Bank now owns 895 shares of the company’s stock valued at $40,000 after buying an additional 278 shares during the period. Quarry LP bought a new position in shares of Mirum Pharmaceuticals during the third quarter worth about $41,000. Finally, CWM LLC lifted its stake in shares of Mirum Pharmaceuticals by 30.8% in the third quarter. CWM LLC now owns 683 shares of the company’s stock worth $50,000 after acquiring an additional 161 shares during the period.

Mirum Pharmaceuticals Company Profile

Mirum Pharmaceuticals, Inc is a late-stage biopharmaceutical company dedicated to the development and commercialization of innovative therapies for rare cholestatic liver diseases. The company’s primary focus lies in addressing the unmet medical needs of patients suffering from genetic and progressive forms of pediatric liver disorders, where limited treatment options currently exist.

Mirum’s lead product candidate, maralixibat (Livmarli), is an ileal bile acid transporter inhibitor designed to reduce systemic bile acid accumulation and alleviate associated pruritus and liver damage.